CONTENTS VOL. 16, 1998/1999

Volume 16, No. 1

Editorial 1

Preclinical Study

Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel *Vinca* alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance *in vivo* and *in vitro* – C. Etievant, J.-M. Barret, A. Kruczynski, D. Perrin, B.T. Hill 3–17

Phase I Studies

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies – H.A. Burris, III, E. Raymond, A. Awada, J.G. Kuhn, T.J. O'Rourke, J. Brentzel, W. Lynch, S.-Y.P. King, T.D. Brown, D.D. Von Hoff 19–27

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy – A.I. Einzig, P.H. Wiernik, S. Wadler, J. Kaplan, L.T. Benson, L. Tentoramano, V. Tan 29–36

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors – N.W. Peacock, H.A. Burris, V. Dieras, L. Smith, G.I. Rodriguez, J.R. Eckardt, S. Fields Jones, J. Hardy, J. Hohneker, J. Bigley, D.D. Von Hoff 37–43

Phase I study of DMP 840 in pediatric patients with refractory solid tumors – J. Thompson, C.B. Pratt, C.F. Stewart, L. Avery, L. Bowman, W.C. Zamboni, A. Pappo 45–49

Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study – J.A. Maroun, D. Stewart, S. Verma, E. Eisenhauer 51–56

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion – G.I. Rodriguez, J.G. Kuhn, G. Weiss, P. De La Cruz, P. New, S.M. Fields, J.R. Eckardt, L. Campbell, G.M. Clark, S.G. Hilsenbeck, D.D. Von Hoff 57–67

Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy – M.J. Edelman, D.R. Gandara, E.A. Perez, D. Lau, I. Lauder, C. Turrell, M. Uhrich, F. Meyers 69–75

Phase II Studies

A phase II study of Temozolomide in advanced untreated pancreatic cancer – M.J. Moore, R. Feld, D. Hedley, A. Oza, L.L. Siu 77–79

Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer – C.M. Haskell, E. Mendoza, K.M.W. Pisters, F.V. Fossella, R.A. Figlin 81–85

Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas – Shreyaskumar R. Patel, M.A. Burgess, N.E. Papadopolous, G. Sidhu, R. Gray, C. Plager, J. Jenkins, R.S. Benjamin 87–92

Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma – M.M. Zalupski, A.F. Shields, P.A. Philip, M. Kraut, P. LoRusso, L.K. Heilbrun, V. Vaitkevicius 93–96

Instructions for authors 97–98

Volume 16, No. 2

Preclinical Studies

Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg^6, D-Trp^{7,9}, MePhe^8]-Substance P {6-11} – J.D. Jonkman-de Vries, H. Rosing, H. Talsma, R.E.C. Henrar, J.J. Kettenes-van den Bosch, A. Bult, J.H. Beijnen 99–111

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units – L.L. Siu, D.D. Von Hoff, A. Rephaeli, E. Izbicka, C. Cerna, L. Gomez, E.K. Rowinsky, S.G. Eckhardt 113–119

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs – T. Noda, T. Watanabe, A. Kohda, S. Hosokawa, T. Suzuki 121–128

Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)-phenoxy]propionate – T.H. Corbett, P. LoRusso, L. Demchick, C. Simpson, S. Pugh, K. White, J. Kushner, L. Polin, J. Meyer, J. Czarnecki, L. Heilbrun, J.P. Horwitz, J.L. Gross, C.H. Behrens, B.A. Harrison, R.J. McRipley, G. Trainor 129–139

Phase I Studies

Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study – D. Lüftner, B. Flath, C. Akrivakis, H.-G. Mergenthaler, U. Ohnmacht, M. Arning, K. Possinger 141–145

Phase I and pharmacokinetic study of intraperitoneal topotecan – S.C. Plaxe, R.D. Christen, J. O'Quigley, P.S. Braly, J.L. Freddo, E. McClay, D. Heath, S.B. Howell 147–153

Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia – S.A. Johnson, D. Catovsky, J.A. Child, A.C. Newland, D.W. Milligan, R. Janmohamed 155–160

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck – J.J. Beitler, R.V. Smith, H. Haynes, C.E. Silver, A. Quish, T. Kotz, M. Serrano, A. Brook, S. Wadler 161–169

Phase II Studies

Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157) – F.L. Meyskens, Jr., J. Jacobson, B. Nguyen, G.R. Weiss, D.R. Gandara, J.S. MacDonald 171–173

Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma – J.A. Ajani, R. Pazdur, P. Dumas, J. Fairweather 175–177

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer – M.J. Edelman, F.J. Meyers, T. Grennan, J. Lauder, J. Doroshow 179–182

Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan – Y. Ito, N. Horikoshi, T. Watanabe, Y. Sasaki, T. Tominaga, T. Okawa, T. Tabei, Y. Kuraishi, K. Tamura, R. Abe, M. Kitajima, S. Yamaguchi, T. Kobayashi, H. Koyama, K. Orita, S. Takashima, Y. Nomura, M. Ogawa 183–190

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase S II trial – R.S. Witte, J. Manola, P.A. Burch, T. Kuzel, E.L. Weinshel, P.J. Loehrer, Sr. 191–195

Instructions for authors 197–198

Volume 16, No. 3

Preclinical Studies

Cryptophycin 1 cellular levels and effects *in vitro* using L1210 cells – B.J. Foster, M. Fortuna, J. Media, R.A. Wiegand, F.A. Valeriote. 199–204

The folate receptor as a potential therapeutic anticancer target – B.A. Gruner, S.D. Weitman. 205–219

Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on *in vitro* colony formation of freshly explanted human tumor cells – E. Izbicka, R. Lawrence, K. Davidson, J.B. Rake, D.D. Von Hoff. 221–225

Compatibility and stability of bryostatin 1 in infusion devices – A.P. Cheung, Y.F. Hallock, B.R. Vishnuvajjala, T. Nguyenle, E. Wang. 227–236

Phase I Studies

Phase I study of paclitaxel administered by ten-day continuous infusion – R.J. Shade, K.M.W. Pisters, M.H. Huber, F. Fossella, R. Perez-Soler, D.M. Shin, J. Kurie, B. Glisson, S. Lippman, J.S. Lee. 237–243

Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily × 5-day schedule – N. Masuda, S. Negoro, K. Takeda, N. Takifuji, T. Hirashima, T. Yana, N. Kurata, T. Kuwabara, S. Kobayashi, S. Kudoh, K. Matsui, M. Takada, M. Fukuoka. 245–254

Phase II Studies

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer – K. Rajagopalan, D. Peereboom, G.T. Budd, T. Olencki, S. Murthy, P. Elson, D. McLain, R. Bukowski. 255–258

A Phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687) – H. Hochster, R. Oratz, D.S. Ettinger, E. Borden. 259–263

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian Experience – J. Latreille, K.A. Gelmon, V. Hirsh, F. Laberge, A.W. Maksymiuk, F.A. Shepherd, F. Delorme, J. Bérille. 265–270

Evoluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study – W.E. Samlowski, D. Lew, P.J. Kuebler, M.A. Kolodziej, J.E. Medina, K.F. Mangan, D.F. Moore, Jr. , D.E. Schuller, J.F. Ensley. 271–274

Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer – A. Mani, J.W. Kugler, J.A. Knost, D.F. Sciortino, J. Gibbons, J.C. Garcia, R.H. Ansari, R.L. Schilsky, E.E. Vokes. 275–278

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma – S. Mani, T. Schiano, J.C. Garcia, R.H. Ansari, B. Samuels, D.F. Sciortino, S. Tembe, K.L. Shulman, A. Baker, S.E. Benner, E.E. Vokes. 279–283

Instructions for authors 285–286

Volume 16, No. 4

Preclinical Studies

Preclinical antitumor activity of XK469 (NSC 656889) – P.M. LoRusso, R. Parchment, L. Demchik, J. Knight, L. Polin, J. Dzubow, C. Behrens, B. Harrison, G. Trainor, T.H. Corbett 287–296

Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells *in vitro* and *in vivo* – I. Pastrone, M. Viale, S. Cafaggi, M.A. Mariggió, A. Parodi, M. Esposito 297–302

Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations – D.R. Shalinksy, J. Brekken, H. Zou, S. Kolis, A. Wood, S. Webber, K. Appelt 303–313

Phase I Studies

PALA *versus* streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma – R.S. Witte, L.M. Ryan, A.J. Schutt, P.P. Carbone, P.F. Engstrom 315–318

Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion – I. Raßmann, R. Thödtmann, M. Mross, A. Hüttmann, W.E. Berdel, Ch. Manegold, H.H. Fiebig, A. Kaeser-Frölich, K. Burk, A.-R. Hanauske 319–324

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors – J.D. Berlin, D.B. Alberti, R.Z. Arzoomanian, C.A. Feierabend, K.J. Simon, K.A. Binger, R.M. Marnocha, G. Wilding 325–330

Phase II Studies

Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study – S.A. Taylor, D.J. Giroux, K.A. Jaeckle, T.J. Panella, S.R. Dakhil, S.C. Schold 331–332

Oral etoposide for patients with advanced adenocarcinoma of the pancreas – E. Thomas, P. Dumas, J.A. Ajani 333–335

A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma – W.J. Berg, J. McCaffrey, L.H. Schwartz, T. Mariani, M. Mazumdar, R.J. Motzer 337–340

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma – R. Pazdur, D.C. Medgyesy, R.J. Winn, S.R. Dakhil, D.F. Moore, Jr., A. Scalzo, P.M. Hoff, S.G. Arbuck, J.L. Abbruzzese 341–346

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124) – F.J. Meyers, D. Lew, P.N. Lara Jr., S. Williamson, E. Marshall, S.P. Balcerzak, S.E. Rivkin, W. Samlowski, E.D. Crawford 347–351

A phase II trial of irinotecan in hormone-refractory prostate cancer – D.M. Reese, S. Tchekmedyian, Y. Chapman, D. Prager, P.J. Rosen 353–359

Contents Volume 16, 1998 361–364

Author Index 365

Instructions for authors 367–368